TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Price & Overview

NASDAQ:TRIB • US8964385046

Current stock price

0.603 USD
+0.01 (+0.84%)
At close:
0.604 USD
+0 (+0.17%)
After Hours:

The current stock price of TRIB is 0.603 USD. Today TRIB is up by 0.84%. In the past month the price decreased by -17.6%. In the past year, price decreased by -77.67%.

TRIB Key Statistics

52-Week Range0.5012 - 17.2
Current TRIB stock price positioned within its 52-week range.
1-Month Range0.5012 - 0.83
Current TRIB stock price positioned within its 1-month range.
Market Cap
11.282M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-2.68
Dividend Yield
N/A

TRIB Stock Performance

Today
+0.84%
1 Week
-1.71%
1 Month
-17.60%
3 Months
-19.19%
Longer-term
6 Months -47.57%
1 Year -77.67%
2 Years -93.37%
3 Years -97.71%
5 Years -99.30%
10 Years -99.79%

TRIB Stock Chart

TRINITY BIOTECH PLC-SPON ADR / TRIB Daily stock chart

TRIB Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to TRIB. When comparing the yearly performance of all stocks, TRIB is a bad performer in the overall market: 94.7% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

TRIB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TRIB. TRIB has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TRIB Earnings

Next Earnings DateApr 3, 2026
Last Earnings DateN/A
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise 3.09%

TRIB Forecast & Estimates

For the next year, analysts expect an EPS growth of 65.8% and a revenue growth 10.13% for TRIB


Analysts
Analysts85.71
Price TargetN/A
EPS Next Y65.8%
Revenue Next Year10.13%

TRIB Groups

Sector & Classification

Index Membership

TRIB Financial Highlights

Over the last trailing twelve months TRIB reported a non-GAAP Earnings per Share(EPS) of -2.68. The EPS increased by 41.07% compared to the year before.


Income Statements
Revenue(TTM)61.55M
Net Income(TTM)-31.79M
Industry RankSector Rank
PM (TTM) N/A
ROA -31.91%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-12.04%
Sales Q2Q%16.15%
EPS 1Y (TTM)41.07%
Revenue 1Y (TTM)8.31%

TRIB Ownership

Ownership
Inst Owners4.55%
Shares18.71M
Float767.49K
Ins OwnersN/A
Short Float %26.25%
Short Ratio0.77

About TRIB

Company Profile

TRIB logo image Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Company Info

IPO: 1992-10-21

TRINITY BIOTECH PLC-SPON ADR

Ida Business Park, Bray, Co Wicklow

DUBLIN WICKLOW IE

CEO: Ronan O'Caoimh

Employees: 401

TRIB Company Website

TRIB Investor Relations

Phone: 1135312955111

TRINITY BIOTECH PLC-SPON ADR / TRIB FAQ

What does TRIB do?

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.


Can you provide the latest stock price for TRINITY BIOTECH PLC-SPON ADR?

The current stock price of TRIB is 0.603 USD. The price increased by 0.84% in the last trading session.


Does TRIB stock pay dividends?

TRIB does not pay a dividend.


How is the ChartMill rating for TRINITY BIOTECH PLC-SPON ADR?

TRIB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the PE ratio for TRIB stock?

TRINITY BIOTECH PLC-SPON ADR (TRIB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.68).


What is the market capitalization of TRIB stock?

TRINITY BIOTECH PLC-SPON ADR (TRIB) has a market capitalization of 11.28M USD. This makes TRIB a Nano Cap stock.